Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled the launch of WHAT THE C@H?!, an educational initiative designed to address the information gap surrounding congenital adrenal hyperplasia (CAH) and acknowledge the challenges faced by the community in managing this condition. “We are proud to introduce this effort to recognize the significant physical and emotional burden individuals and their families experience living with CAH,” stated Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. “We hope this educational initiative, which was informed by insights from the c ..read more

Bio-Techne Corporation (NASDAQ: TECH), a renowned global life sciences company specializing in innovative tools and bioactive reagents for both research and clinical diagnostics, has officially initiated legal proceedings in the Unified Patent Court of Europe. The aim is to address the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc. Under its Advanced Cell Diagnostics (ACD) brand, Bio-Techne holds patents encompassing various aspects of its RNAscope technology. Renowned as a pioneer in spatial biology, Bio-Techne boasts a vast portfolio comprising over 50,0 ..read more

Moderna, Inc. (NASDAQ: MRNA) and OpenAI have announced a collaborative effort aimed at harnessing the potential of artificial intelligence (AI) to revolutionize both business and healthcare. Moderna, known for its digital-first approach and early adoption of machine learning, is poised to integrate generative AI into its operations seamlessly, building upon its strong data foundation and culture of continuous learning. The partnership between the two organizations commenced in early 2023 with the introduction of mChat, Moderna’s customized instance of ChatGPT developed internally on OpenAI’s ..read more

CVS Health® (NYSE: CVS) revealed today a significant investment of $19.2 million, facilitated via Boston Financial, earmarked for the construction of 85 new affordable housing units in Arvada, Colorado. This initiative, executed in partnership with Family Tree and BlueLine Development, underscores CVS Health’s dedication to enhancing the well-being of individuals nationwide, starting with ensuring access to high-quality, secure, and affordable housing, particularly in historically marginalized areas. Frank J. Benedetto, Regional Director of Sales and Account Management at Aetna®, a CVS Health ..read more

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics have announced an exclusive licensing agreement, granting Vertex access to TreeFrog’s cutting-edge cell manufacturing technology, C-Stem™. This collaboration aims to optimize the production of Vertex’s cell therapies tailored for treating type 1 diabetes (T1D). Together, TreeFrog and Vertex will work on scaling up the C-Stem™ process to generate and amplify cells essential for Vertex’s T1D treatments. C-Stem™, TreeFrog’s proprietary technology, is engineered to replicate the natural microenvironment, enabling exponent ..read more

Roche Reports 2% Growth in Group Sales Despite Currency Impact In the first quarter of 2024, Roche saw a 2% increase in group sales at constant exchange rates (CER), though a 6% decrease was observed in Swiss francs (CHF) due to currency fluctuations. The growth was primarily driven by strong performances in newer medicines and diagnostics. Excluding COVID-19-related products, sales rose by 7%. Looking ahead, the company expects no significant further impact from COVID-19-related sales decline. The appreciation of the Swiss franc against most currencies contributed to the 6% decrease in repor ..read more

Novartis and Medicines for Malaria Venture (MMV) have unveiled encouraging results from their phase II/III CALINA trial, indicating that a newly formulated version of Coartem® (artemether-lumefantrine) tailored for infants weighing under 5kg with malaria demonstrates the necessary pharmacokinetic profile, along with commendable efficacy and safety. Conducted across multiple African nations, the findings will be presented at the Multilateral Initiative on Malaria (MIM Society) 8th Pan-African Malaria Conference in Kigali and have been forwarded for regulatory assessment. Malaria remains a formi ..read more

Voydeya (danicopan) Receives EU Approval as Supplemental Treatment for Adults with PNH and Residual Hemolytic Anemia Voydeya (danicopan) has gained approval in the European Union (EU) to be used alongside ravulizumab or eculizumab for managing adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who continue to experience hemolytic anemia. This approval marks a significant advancement, offering a novel therapeutic option for approximately 10-20% of PNH patients who encounter clinically significant extravascular hemolysis (EVH) despite being treated with a C5 inhibitor. The decision by ..read more

Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), is extending an invitation to consumers to participate in future campaigns featuring their flagship brands, such as BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, their loyalty rewards program. Starting today, individuals, whether current patients or prospective ones, can apply for the opportunity to be showcased in upcoming brand initiatives. The initial open casting call for BOTOX® Cosmetic drew approximately 20,000 entries, culminating in a compelling campaign highlighting a diverse array of patients sharing their genu ..read more

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled positive top-line results from its Phase 2 SAVITRI™ trial. This study, employing a randomized, double-blind, and placebo-controlled design, evaluated the efficacy and safety of NBI-1065845 in adult patients grappling with major depressive disorder (MDD). NBI-1065845 is an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) positive allosteric modulator (PAM) being developed as a potential treatment for MDD patients who have not responded to at least one antidepressant during their current depressive episode ..read more